TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05372276

Intervention type: OTHER
Intervention: Assessment 1
Description: Mental Toughness Questionnaire in Sport

Intervention type: OTHER
Intervention: Assessment 1
Description: Mental Toughness Questionnaire in Sport

Intervention type: OTHER
Intervention: Assessment 1
Description: Mental Toughness Questionnaire in Sport

Intervention type: OTHER
Intervention: Assessment 2
Description: Sport Imagery Questionnaire

Intervention type: OTHER
Intervention: Assessment 2
Description: Sport Imagery Questionnaire

Intervention type: OTHER
Intervention: Assessment 2
Description: Sport Imagery Questionnaire

Intervention type: OTHER
Intervention: Assessment 3
Description: The Pittsburgh Sleep Quality Index

Intervention type: OTHER
Intervention: Assessment 3
Description: The Pittsburgh Sleep Quality Index
Study: NCT06101992

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsules are composed by lactose monohydrate, corn starch, croscarmellose sodium, magnesium stearate
Study: NCT05372276

Intervention type: OTHER
Intervention: Assessment 3
Description: The Pittsburgh Sleep Quality Index

Intervention type: OTHER
Intervention: Assessment 4
Description: The Perceived Stress Scale (PSS)

Intervention type: OTHER
Intervention: Assessment 4
Description: The Perceived Stress Scale (PSS)

Intervention type: OTHER
Intervention: Assessment 4
Description: The Perceived Stress Scale (PSS)
Study: NCT06265207

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Before the mammography, a 20-minute relaxing video featuring nature and forest views will be watched with VR SHINECON 360 degree glasses. Since it is seen in the literature that watching a video for 20 minutes provides effective results, the video viewing time was determined as 20 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: routine maintenance
Description: routine maintenance
Study: NCT06291896

Intervention type: DEVICE
Group type: OTHER
Intervention: MammoWave
Description: Women undergoing conventional breast screening examination will be asked by the clinical staff if they are interested in taking part in the study.~A short visit should be performed to check the inclusion/exclusion criteria, review demographic data, and the volunteer's medical history. After performing this visit, the volunteers will perform the MammoWave exam on both their breasts.~The exam will be composed of two phases: data acquisition and data processing. During the acquisition, which should take about 8 minutes, the volunteers would be lying down in a prone position, on the bed which is part of MammoWave.~When the acquisition is completed, the data will be processed through a dedicated microwave imaging algorithm. The output will be composed of microwave images, plus parameters describing the images. MammoWave output will also comprise a label obtained using an optimized classification algorithm.
Study: NCT05535439

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EBUS-TBNA using 22 G EBUS-FNB Device OR 19 G EBUS-FNA needle
Description: Both arm will be interventional where mediastinal lymph nodes will be sampled by two typs of needle

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EBUS-TBNA using 22 G EBUS-FNB Device OR 19 G EBUS-FNA needle
Description: Both arm will be interventional where mediastinal lymph nodes will be sampled by two typs of needle
Study: NCT05026931

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foam rolling
Description: Group A will be treated with foam rolling effect on quadriceps, hamstring and calf muscle length. 5 min cycle ergometry, 6 min foam rolling 3 times for 30sec.For three session per week will be given atleast for 2 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching exercises
Description: Group B will be treated with stretching exercises effect on quadriceps, hamstring and calf muscle length. 5 min cycle ergometry, 6 min foam rolling 3 times for 30sec.For three session per week will be given atleast for 2 months.
Study: NCT05185921

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trial-based Cognitive therapy
Description: The virtual CBT will be provided by 02 psychotherapists, who will follow a protocol developed for this study. The number of sessions will be eight, which will be held weekly, projecting an intervention time of 2 to 3 months considering the possibility of rescheduling any of the sessions for reasons derived from the participant People with relevant cognitive impairment that prevents them from answering the questionnaire questions or providing informed consent are excluded.
Study: NCT04271449

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS (transcranial direct current stimulation)
Description: Non invasive functional brain stimulation that allows to modulate the excitability of a targeted area (inhibitory or excitatory) thanks to a small current that goes beyond two electrodes. For this arm, the targeted are will be the cerebellum.~Prismatic googles will also be used in the same way in all groups during prism exposure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality device
Description: Non invasive functional brain stimulation that allows to modulate the excitability of a targeted area (inhibitory or excitatory) thanks to a small current that goes beyond two electrodes. For this arm, the targeted are will be the cerebellum.~Prismatic googles will also be used in the same way in all groups during prism exposure.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS (transcranial direct current stimulation)
Description: Non invasive functional brain stimulation that allows to modulate the excitability of a targeted area (inhibitory or excitatory) thanks to a small current that goes beyond two electrodes. For this arm, the targeted are will be either the cerebellum or the primary motor cortex, but the stimulation will be turned off after 15 seconds to insure a sham condition.~Prismatic googles will also be used in the same way in all groups during prism exposure.
Study: NCT05745376

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Farm to ECE programming
Description: Students and parents at this center will receive program elements described in arm descriptions.
Study: NCT05973682

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-isometric relaxation and Conventional treatment
Description: The term refers to the effect of subsequent relaxation experienced by a muscle or group of muscles, after brief periods during which an isometric contraction has been performed. Post isometric relaxation technique was applied to levator scapulae for 5 repetition using 20% of maximal isometric contraction for 7-10 sec. with complete relaxation of all element, the stretch is maintained for 30 sec.~+ hot pack and TENS at neck area for 10 mint upper trapezius, levator scapulae and pectoralis stretching 3 times with 30 second hold. static stretching exercises two sessions per week for 3 weeks were given to each patient

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physical Therapy
Description: Conventional Physical Therapy; hot pack and TENS at neck area for 10 mint upper trapezius, levator scapulae and pectoralis stretching 3 times with 30-second hold. static stretching exercises, two sessions per week for 3 weeks were given to each patient

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: Conventional Physical Therapy; hot pack and TENS at neck area for 10 mint upper trapezius, levator scapulae and pectoralis stretching 3 times with 30-second hold. static stretching exercises, two sessions per week for 3 weeks were given to each patient
Study: NCT05492318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Givinostat 10 mg/mL
Description: 10 mg/mL oral suspension. Givinostat 10 mg/ml oral suspension was administered once, in the morning, in Days 1, 2, 6, 7, 17 and 18), and twice a day (50 mg as oral suspension), in the morning and in the evening, from the Day 4 to Day 18. On Day 19, only the morning dose was administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam 1mg/ml IV
Description: Midazolam 1 mg/ml, solution for intravenous administration. Midazolam 1mg/ml IV, single dose, was administered on Days 1, 6 and 17, 1 hour after the planned morning time of givinostat administration. Midazolam IV were administered with the subjects in a semi-recumbent position. Subjects remained semirecumbent until at least 3 hours post-dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam 2.5 mg oromucosal solution
Description: Dose: 2.5 mg oromucosal solution. Midazolam 2.5 mg single oral solution was administered on Days 2, 7 and 18, 1 hour after the planned morning time of givinostat administration.~Oral midazolam (and dabigatran etexilate) was administered following an overnight fasting of at least 8 hours and subjects remained fasted until at least 3 hours post-dose.~Oral midazolam (and dabigatran etexilate) was administered with 150 mL of water. Except for water given with the investigational products, no fluids were allowed from 1 hour before midazolam and dabigatran dosing until 2 hours postdose. Water was provided ad libitum at all other times. Midazolam (and dabigatran etexilate) were administered with the subjects in a semi-recumbent position. Subjects remained semirecumbent until at least 3 hours post-dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 75 mg oral hard capsules
Description: Dose: 75 mg; Dosage form: hard capsules On Days 1, 6 and 17, dabigatran etexilate 75 mg was administered (with midazolam 1mg IV) 1 hour after the planned morning time of givinostat administration.~Dabigatran etexilate (and midazolam) was administered following an overnight fasting of at least 8 hours and subjects remained fasted until at least 3 hours post-dose Oral dabigatran etexilate (and oral midazolam) was administered with 150 mL of water. Except for water given with the investigational products, no fluids were allowed from 1 hour before dabigatran (and midazolam) dosing until 2 hours postdose. Water was provided ad libitum at all other times. Dabigatran etexilate (and Midazolam) was administered with the subjects in a semi-recumbent position. Subjects remained semirecumbent until at least 3 hours post-dose.
Study: NCT06013917

Intervention type: DEVICE
Intervention: Cardiac Monitoring
Description: FDA cleared ECG monitoring device that will be used to obtain ECG recordings and capture cardiac arrhythmias/events from participants
Study: NCT06073522

Intervention type: OTHER
Intervention: Artificial Intelligence for combining multi-domain data acquisition
Description: Artificial Intelligence and machine learning techniques to combine data coming from multidomains data collection (such as clinical multiaxial assessments and questionnaires, Neuroimaging, Upper limb movement analysis during clinical assessment and daily life )

Intervention type: OTHER
Intervention: Artificial Intelligence for combining multi-domain data acquisition
Description: Artificial Intelligence and machine learning techniques to combine data coming from multidomains data collection (such as clinical multiaxial assessments and questionnaires, Neuroimaging, Upper limb movement analysis during clinical assessment and daily life )
Study: NCT05213806

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Withholding feeds around transfusion
Description: Withholding enteral feeds for preterm infants (\<30 weeks) around the time of blood transfusions to determine if any impact on the development and/or severity of Necrotizing Enterocolitis.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continued feeds around transfusion
Description: Continued enteral feeds
Study: NCT04979299

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wheelchair
Description: Patient will be asked to sit in a wheelchair, and a 5-minute video recording of spontaneous speech capturing the semi-structured iCGI interview is made.
Study: NCT05756140

Intervention type: OTHER
Intervention: No intervention
Description: No Control
Study: NCT05821621

Intervention type: OTHER
Intervention: no intervention
Description: observational study : there is no intervention
Study: NCT04829019

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Osimertinib and whole-brain irradiation
Description: Osimertinib at a dose of 80 mg once per day, and WBI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osimertinib
Description: Osimertinib at a dose of 80 mg once per day, until unacceptable adverse events or disease progression occurred. WBI could be given to patients in experimental arm at any time base on investigator's decision after treatment initiated.
Study: NCT05676255

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitively-Based Compassion Training for Survivors
Description: CBCT-S is a secular adaptation of techniques derived from traditional Tibetan Buddhist methods for cultivating compassion known as lo-jong. CBCT-S will be administered to breast cancer survivors and will not including supportive partners.~Module 1 (Week 1): Overview and Connecting to A Moment of Nurturance~Module 2 (Week 2) Developing Stable and Clear Attention~Module 3 (Week 3): Enhancing Self Awareness~Module 4 (Week 4): Cultivating Self compassion Part 1: Accepting our Suffering~Module 5 (Week 5): Self Compassion Part 2: Finding Meaning in Suffering.~Module 6(Week 6): Expanding our Circle of Concern~Module 7 (Week 7): Deepening Gratitude and Tenderness~Module 8 (Week 8): Harnessing the Power of Compassion

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitively-Based Compassion Training for Dyads
Description: CBCT-D is a secular adaptation of techniques derived from traditional Tibetan Buddhist methods for cultivating compassion known as lo-jong. CBCT-D will be administered to breast cancer survivors and supportive partners together.~Module 1 (Week 1): Overview and Connecting to A Moment of Nurturance~Module 2 (Week 2) Developing Stable and Clear Attention~Module 3 (Week 3): Enhancing Self Awareness~Module 4 (Week 4): Cultivating Self compassion Part 1: Accepting our Suffering~Module 5 (Week 5): Self Compassion Part 2: Finding Meaning in Suffering.~Module 6(Week 6): Expanding our Circle of Concern~Module 7 (Week 7): Deepening Gratitude and Tenderness~Module 8 (Week 8): Harnessing the Power of Compassion

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: HE focuses on topics relevant to health and cancer, but is also intended for individuals who are not cancer survivors themselves.~HE will be administered to both breast cancer survivors and supportive partners together.~Module I (Week 1): Cancer Advocacy.~Module II (Week 2): Health Through the Lifespan.~Module III (Week 3): Nutrition.~Module III (Week 4): Nutrition.~Module IV (Week 5): Physical Activity.~Module V (Week 6): Sleep.~Module VI (Week 7): Stress.~Module VII (Week 8): Mental Health and Social Support.
Study: NCT06282497

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Optimised neck CTV
Description: neck CTV delineation extends from the lateral process of C1

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: standard neck CTV
Description: neck CTV delineation extends from skull base
Study: NCT05384158

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive behavioral therapy
Description: cognitive behavioral therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: valuation with instruction
Description: repeat laboratory sessions of computerized learning game

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: valuation without instruction
Description: repeat laboratory sessions of computerized learning game
Study: NCT05019417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycerol Phenylbutyrate 1100 MG/ML
Description: Daily adminisitraion of the study drug (three times a day) in escalting dose over 4 months
Study: NCT05061641

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: The delivery outcomes of the three groups were compared, including the rate of premature delivery (\<37 weeks of gestation), the rate of early premature delivery (\<32 weeks of gestation), and the need for anti-tocolysis treatment. Rates of premature rupture of membranes (\<37 weeks), neonatal perinatal mortality and morbidity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: The delivery outcomes of the three groups were compared, including the rate of premature delivery (\<37 weeks of gestation), the rate of early premature delivery (\<32 weeks of gestation), and the need for anti-tocolysis treatment. Rates of premature rupture of membranes (\<37 weeks), neonatal perinatal mortality and morbidity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: The delivery outcomes of the three groups were compared, including the rate of premature delivery (\<37 weeks of gestation), the rate of early premature delivery (\<32 weeks of gestation), and the need for anti-tocolysis treatment. Rates of premature rupture of membranes (\<37 weeks), neonatal perinatal mortality and morbidity.
Study: NCT05539755

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non surgical debridement of peri-implantitis
Description: The procedure was standardized as follows: the implants' prosthesis was checked for its cleansability, and retrieved when possible. Then, the prosthesis was modified following a previously described elsewhere (de Tapia et al., 2019). After local anaesthesia (articaine 4% and adrenaline 1:100,000), the implant surfaces were cleaned with ultrasonic devices (Newtron P5, Satelec Acteon; Olliergues, France) with the steel alloy H3 dental ultrasonic scaler tip (H3, Satelec Acteon; Olliergues, France), curettage (SyG 7/89 Everdge, Hu-Friedy; Chicago, IL, USA) of the bone defect was performed, and glycine air powder applied submucosally (Air-flow® powder subgingival PERIO, EMS; Nyon, France) with an air-flow piezon device (Air-flow master piezon®, EMS, Nyon; France).~Oral hygiene instructions were given and metronidazole 500 mg every 8 h for 7 days was prescribed. Patients were scheduled at 3 months for supragingival plaque control and supragingival debridement, if needed.
Study: NCT04988841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MaaT013
Description: study is an experimental drug , produced by MaaT Pharma, and composed of pooled-donor, full-ecosystem intestinal microbiome (455 species approximately against 274 on average)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MaaT013
Description: study is an experimental drug , produced by MaaT Pharma, and composed of pooled-donor, full-ecosystem intestinal microbiome (455 species approximately against 274 on average)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Anti cytotoxicT-lymphocyte-associated protein 4 ( immunothérapy)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ipilimumab
Description: Anti cytotoxicT-lymphocyte-associated protein 4 ( immunothérapy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: AntiPD1 ( immunothérapy)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nivolumab
Description: AntiPD1 ( immunothérapy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MoviPrep
Description: Osmotic laxative solution : patients take a single dose of two liters of Moviprep® or equivalent the night before the first administration of experimental treatment (Fecal microbiota transfer or placebo)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MoviPrep
Description: Osmotic laxative solution : patients take a single dose of two liters of Moviprep® or equivalent the night before the first administration of experimental treatment (Fecal microbiota transfer or placebo)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normacol
Description: hypertonic enema solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normacol
Description: hypertonic enema solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Maat013
Description: expérimental drug placebo of MaaT013
Study: NCT04942249

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT03911336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group A - test:Tooth extraction and intake of NSAID and a non-NSAID
Description: Tooth extraction and intake of an NSAID (i.e. Ketoprofen ER 50 mg) at 8 AM and a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 2 PM and 8 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group B - Control 1: tooth extraction and intake of NSAID and a non-NSAID
Description: Tooth extraction and intake of an NSAID (i.e. Ketoprofen ER 50 mg) at 8 PM and a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 8 AM and 2 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group C - Control 2: tooth extraction and intake of a Non-Nsaid
Description: Tooth extraction and intake of a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 8AM, 2 PM and 8 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.
Study: NCT00012935

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Help with decision making on prostate cancer treatment
Study: NCT04997746

Intervention type: BEHAVIORAL
Intervention: Multiprofessional educational interventions
Description: Preventive educational interventions

Intervention type: BEHAVIORAL
Intervention: Multiprofessional educational interventions
Description: Preventive educational interventions

Intervention type: BEHAVIORAL
Intervention: Multiprofessional educational interventions
Description: Preventive educational interventions

Intervention type: OTHER
Intervention: Measurement of anthropometric measurements
Description: Measurement of height (in meters), weight (in kilograms), knee height, arm circumference and calf circumference (in centimeters)
Study: NCT00539799

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisolone
Description: 5 - 7.5 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo to prednisolone
Study: NCT06067451

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART GOALS Setting Tool/ Protocol
Description: The participants randomized to the study group will receive the SGSP, consisting of the SMART Goal Selection Guide (SGSG) and Weekly Goal Monitoring Tool (WGMT), which will be used in tandem. The participant will first receive the SGSG which will highlight 3 domains of SMART goals (exercise, diet, and behavior). Each domain will have 1 predetermined and unchanging primary goal which will serve as the standard for all participants to strive for.